本季度信息
2025年第三季度，丽珠医药集团实现营业收入约人民币28.44亿元，同比增长1.60%。同期，扣除非经常性损益后的净利润约人民币4.54亿元，同比下降4.58%。
年初至第三季度累计营业收入约人民币91.16亿元，同比增长0.38%；同期累计扣非净利润约人民币17.12亿元，同比增长4.98%。经营活动产生的现金流量净额约为人民币25.25亿元，同比增长9.42%，显示出较为稳健的资金回笼能力。
从成本结构看，2025年前三季度销售费用约人民币26.04亿元，较上年同期增长约6%，主要因市场推广及渠道投入增加。管理费用约人民币4.50亿元，略有下降。研发费用约人民币6.83亿元，占营业收入比重约7.49%，公司研发投入总体保持在较高水平，以支持在研项目的持续进展。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.